Keratoacanthoma - Queratoacantoma
☆ En los resultados de 2022 del Stiftung Warentest de Alemania, la satisfacción del consumidor con ModelDerm fue sólo ligeramente inferior que con las consultas de telemedicina pagadas.
Típico Queratoacantoma (Keratoacanthoma)
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) es un tumor cutáneo frecuente, conocido por su rápido crecimiento y su capacidad de retroceder por sí solo. Suele presentarse en hombres mayores de piel clara, con antecedentes de daño solar. Aunque la extirpación quirúrgica mediante escisión o cirugía micrográfica de Mohs es el tratamiento habitual, existen otras opciones terapéuticas disponibles.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) es un tumor de bajo grado que se origina en ciertas glándulas cutáneas y se asemeja al squamous cell carcinoma (SCC) al observarlo bajo el microscopio. Actualmente hay un debate sobre si el KA debería clasificarse como una forma de CCE invasivo.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) es el segundo tipo de cáncer más frecuente en la población, especialmente en las personas de edad avanzada. La cirugía suele ser el tratamiento de elección para el cSCC, pero en pacientes que no pueden someterse a ella o que optan por no hacerlo, pueden considerarse otras opciones, como los tratamientos intralesionales. Se han utilizado tratamientos intralesionales tradicionales (methotrexate or 5-fluorouracil), y actualmente se investigan nuevos enfoques, como la inmunoterapia intralesional y la viroterapia oncolítica. En este documento analizaremos diferentes tratamientos intralesionales para el cSCC, que van desde métodos clásicos hasta estrategias de vanguardia.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Bajo el microscopio, el queratoacantoma (keratoacanthoma) se parece mucho al carcinoma de células escamosas. Si bien algunos patólogos clasifican el queratoacantoma (keratoacanthoma) como una entidad distinta y no como una enfermedad maligna, alrededor del 6% de los queratoacantoma (keratoacanthoma) clínicos e histológicos progresan a cánceres de células escamosas invasivos y agresivos.
○ Diagnóstico y tratamiento
#Dermoscopy
#Skin biopsy